Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05736224 · ClinicalTrials.gov registry record · Phase 1
Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen
A Phase 1 study of Skin Cancer, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05736224: Completed Phase 1 study of Skin Cancer, sponsored by Yale University.
NCT05736224 is a Phase 1 study of Skin Cancer that has completed, run by Yale University. The registered enrollment target is 30 participants, below the 463-participant average among 40 other Skin Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05736224, a Phase 1 study of Skin Cancer, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to evaluate the effects of a novel sunscreen formulation by assessing the extent of ultraviolet radiation (UVR)-induced direct and indirect cellular and DNA damage to human skin, in the presence vs absence of the sunscreen, in a population of healthy adults with fair skin (Fitzpatrick Scale type I, II or III).
Primary Outcome
Ultraviolet radiation (UVR) exposure are indicative of direct DNA damage. DNA will be prepared and assayed by ELISA for quantification of CPDs. CPDs measured in samples obtained immediately after UVR exposure are indicative of direct DNA damage. DNA from skin biopsies was used to quantify the level of DNA damage, represented by CPD levels detected by enzyme-linked immunosorbent assay (ELISA)
Conditions Studied
Interventions
- DRUG Sunscreen
- OTHER UV Light
Study Locations (1)
Connecticut
- Yale School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-05-15 |
| Est. Completion | 2023-09-01 |
| Phase | Phase 1 |
What the finished NCT05736224 record still lists
NCT05736224 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 463-participant average among 40 other Skin Cancer trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Skin Cancer appearing as the primary indexed condition, and to 2 interventions - of which Sunscreen is the first listed.
NCT05736224 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05736224 about?
NCT05736224 is a clinical study titled "Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen". The primary objective of this study is to evaluate the effects of a novel sunscreen formulation by assessing the extent of ultraviolet radiation (UVR)-induced direct and indirect cellular and DNA damage to human skin, in the presence vs absence of the sunscreen, in a population of healthy adults wit...
What is the current status of trial NCT05736224?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-05-15. Estimated completion is 2023-09-01.
What conditions does trial NCT05736224 study?
This clinical trial studies the following conditions: Skin Cancer.
What interventions are being tested in trial NCT05736224?
The interventions under investigation include: Sunscreen (DRUG), UV Light (OTHER).
Who is sponsoring clinical trial NCT05736224?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05736224 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05736224's enrollment target sits among peer trials
30 31st of 40 higher than 9 of 40 other Skin Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Skin Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
RECRUITING · Phase 1
-
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
ACTIVE NOT RECRUITING · Phase 1
-
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
ACTIVE NOT RECRUITING · Phase 1
-
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma
COMPLETED · Phase 1
-
Rural Adult and Youth Sun Protection Study
RECRUITING · NA
-
TIL Therapy in cSCC and MCC
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI